Lipid Nanoparticles IP Landscape

Lipid Nanoparticles in Drug Delivery: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent Valuation Analysis, Patentability, Freedom to Operate, Pockets of Innovation, Existing White Spaces, and Claim Analysis)

  • Lowest Price Guaranteed From USD 1,899

  • Published
    March 2023

  • Slides
    182

  • View Count
    594

  • Buy Now

Example Insights

Lipid-Nanoparticles-in-Drug-Delivery-IPL-Context-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-Drug-Delivery-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-worldwide-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-developments-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-nanoparticles-thumb
Lipid-Nanoparticles-in-Drug-Delivery-IPL-innovation-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-launch-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-Valuation-Analysis-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-Patent-Claims-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-CPC-Families-thumb
Lipid-Nanoparticles-in-Drug-Delivery-IPL-Patent-Innovations-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-Excel-Deliverable-thumb Lipid-Nanoparticles-in-Drug-Delivery-IPL-the-report-thumb    

Overview

Low drug solubility and its corresponding impact on bioavailability have remained a primary cause of concern with several marketed as well as clinical stage drugs. According to the Journal of Analytical and Pharmaceutical Research, 70% of the 50 drugs approved by the USFDA in 2021 were poorly soluble. Moreover, approximately 40% of marketed pharmacological products and close to 90% of drug candidates under development, have been associated with solubility and / or permeability issues, resulting in poor bioavailability. It is worth noting that, every year, a large number of drugs fail to reach the market due to poor bioavailability and issues associated with aqueous solubility. As a result, the industry is actively seeking various tools / methods to mitigate this challenge. Amongst the various approaches for bioavailability enhancement of therapeutic interventions, lipid nanoparticles (LNPs) and other lipidic excipients have gained sufficient attention from drug developers owing to their ability to act as drug carriers for complex, albeit highly promising therapeutics. Many studies have indicated that lipid-based formulations are capable of solving the complex drug delivery challenges currently faced by this industry. This can be attributed to the versatility of such molecules in terms of structure and functionality, as well as their ability to enhance the solubility and bioavailability of poorly water-soluble (hydrophobic) drugs.

It is worth highlighting that, currently, lipid nanoparticles / lipids are the most commonly used drug delivery systems, specifically for mRNA therapeutics and vaccines. In fact, LNPs have been used in several mRNA-based COVID-19 vaccines to encapsulate and deliver genetic material to the target cells. As a result, the demand for lipid nanoparticles as drug delivery systems has grown considerably over the years. Presently, several studies are underway to evaluate the potential of next-generation lipid nanoparticles as effective drug delivery systems, aiming to enable the development of therapies with high efficacy and bioavailability. Given the extensive research activity, the intellectual capital related to the use of LNPs in drug delivery has also grown over time. Therefore, it is important to keep track of both pockets of innovation and key areas of improvement for stakeholders to remain competitive in this upcoming field of the healthcare domain. This report captures some of the key R&D trends and provides competitive intelligence on intellectual property related to lipid nanoparticles and their applications in drug delivery.

Scope of the Report

The Lipid Nanoparticles in Drug Delivery: Intellectual Property Landscape report features an extensive study of some of the key historical and contemporary intellectual property (IP) documents (featuring granted patents, patent applications and other documents), describing the various applications of lipid nanoparticles in drug delivery. The insights generated in this report have been presented across two deliverables, namely a MS Excel workbook and a MS PowerPoint deck, summarizing the ongoing activity in this domain. Key inclusions are briefly described below:

  • Overall Intellectual Property Landscape

An analytical perspective of the various patents and affiliated IP documents that have been published related to lipid nanoparticles in drug delivery, since 1977. An in-depth analysis of published IP documents, representing unique patent families across various global jurisdictions, featuring insightful inferences related to both historical and recent R&D trends within this niche, yet rapidly evolving segment of the biotechnology and pharmaceutical industry.

  • Popular / Relevant Prior Art Search Expressions

An examination of IP literature, shortlisting key words and phrases used to describe lipid nanoparticles in drug delivery. The analysis also includes details on the historical use of the aforementioned terms across different IP filings, key affiliated terms (which can be used to identify other relevant IP search terms and establish relationships between prior art search expressions), and other related trends.

  • Patent Valuation Analysis

A competitive benchmarking and valuation analysis of the key members of unique patent families captured in the report, taking into consideration important parameters, such as type of IP document, year of application, time to expiry, number of citations and jurisdiction (factoring in value associated with the gross domestic product (GDP) of a particular region).

  • Patentability and Freedom to Operate

A systematic approach to identify relevant areas of innovation by analyzing published IP documents (representative of unique patent families), by defining the uniqueness of patented / patent pending innovations, in order to assess the scope of patentability in this domain, and pinpoint jurisdictions wherein new and / or modified claims may be filed without infringing on existing IP. 

  • Analysis of Patent Applications

A detailed summary of the various patent applications (representative of unique patent families) that were filed across different jurisdictions and their relative value in the IP ecosystem. The analysis classified the intellectual capital in terms of type of innovation and the innovation (such as a product class, enabling technologies or method of use), thereby, offering the means to identify active arenas of research and assess innovation-specific IP filing trends.

  • Analysis of Granted Patents

An analysis of the granted patents (representative of unique patent families) across different global jurisdictions and their relative value in the IP ecosystem. The analysis also features a meaningful classification system, segregating granted IP into relevant categories (namely type of innovation and innovation) to help develop a detailed perspective on the diversity of intellectual capital (having marketing exclusivity) related to lipid nanoparticles in drug delivery, and the assessing likelihood for innovators to enter into promising research areas. 

  • Pockets of Innovation and White Spaces

An insightful analysis of the various CPC codes used in published IP literature (representative of unique patent families) and their affiliated families, offering the means to identify historical and existing pockets of innovation (based on the functional area / industry described by the elaborate and systematic IP classification approach, mentioned earlier); the analysis also features a discussion on prevalent white spaces (based on type of innovation and innovation) in this field of research.

  • Claim Analysis

One of the objectives of the report was to analyze and summarize key inferences from the independent claims mentioned in granted, active patents (representative of unique patent families) in the dataset. Using a systematic segregation approach, we have analyzed trends associated with the preamble, type of patent (product patent or method patent), type of claim (open ended claim or closed ended claim) and key elements of a claim (individual aspects of an innovation that are covered in a singular claim).

Frequently Asked Questions

Question 1: What are lipid nanoparticles?
Answer: Lipid nanoparticles are nanostructured spherical vesicles composed of ionizable lipids with particle size of approximately 100 nm. 

Question 2: Why are lipid nanoparticles used for drug delivery? 
Answer: Due to their unique physical and chemical properties, lipid nanoparticles have emerged as the principal excipient for the delivery of various types of therapeutics, including small molecules, gene therapies, proteins, peptides and DNA / RNA.

Question 3: What are the advantages of lipid nanoparticles in drug delivery? 
Answer: Owing to their numerous advantages, including the ability to control and modify drug release, their biocompatible and biodegradable nature, low toxicity, and ease of production, lipid nanoparticles have become a preferred drug delivery system. Further, they exhibit high drug payload, enable targeted drug delivery and can cross biological barriers such as the blood-brain barrier.

Question 4: What are applications of lipid nanoparticles in the pharmaceutical industry beyond drug delivery? 
Answer: Beyond drug delivery, lipid nanoparticles have potential applications in treatment of cancer and genetic diseases. Further, they are also used in gene editing and medical imaging.

Question 5: What is the current intellectual property landscape of lipid nanoparticles in drug delivery?
Answer: Given the surge in development of LNP-based drug delivery systems in recent years, there has been increase in patent filings trend related to LNP technology, with numerous patents already been filed by various companies and academic / research institutions. As per our research, more than 5,500 patents focused on LNPs and their applications in drug delivery have been filed / granted till date. Of these, 20% of the patents are granted patents.

Question 6: Which are the major innovation categories in the intellectual property domain of lipid nanoparticles in drug delivery?
Answer: The intellectual property domain of lipid nanoparticles in drug delivery encompasses a wide range of innovations, such as compositions of lipid nanoparticles, types of lipid nanoparticles used in drug delivery and formulation methods for lipid nanoparticles.

Contents

DELIVERABLE OUTLINES

Excel Deliverable

Sheet 1 features details on how the input data for this project was collated, including the search strings used to query a popular patent database (lens.org), and data segregation notes. 

Sheet 2 is a summary MS Excel dashboard, offering a detailed, graphical perspective of the intellectual property landscape of lipid nanoparticles in drug delivery. It includes pictorial representations of the overall patent landscape, IP documents representing patent families that describe unique innovations related to lipid nanoparticles in drug delivery, trends related to patent applications (including insights on patentability and freedom to operate), trends related to granted patents (including insights on patentability and freedom to operate), key inferences from a proprietary claim analysis, list of popular CPC symbols (featuring key pockets of innovation) and list of popular applicants (shortlisted based on number of published IP documents).
    
Sheet 3 is an elaborate tabular representation of the overall IP landscape, featuring information on the various types of IP documents related to lipid nanoparticles in drug delivery, which have been published since 1977. 

Sheet 4 is an excerpt of the data presented in the previous sheet, featuring published IP documents, that represent unique patent families across various global jurisdictions. This dataset has been analyzed in detail, in the report. 

Sheet 5 includes a tabular representation of the key words and phrases (prior art search expressions) that are used to describe lipid nanoparticles in drug delivery and affiliated intellectual capital.

Sheet 6 is a subset of sheet 4, featuring all the patent applications, covering innovations related to lipid nanoparticles in drug delivery.

Sheet 7 is a subset of sheet 4, featuring all the granted patents, covering innovations related to lipid nanoparticles in drug delivery. 

Sheet 8 is an insightful summary of the key inferences from the independent claims of the granted, active patents in the dataset. It involves the use of a systematic segregation approach to analyze key trends associated with the preamble, type of patent (product patent or method patent), type of claim (open ended claim or closed ended claim) and key elements of a claim (individual aspects of an innovation that are covered in a singular claim).

Sheet 9 provides insights related to some of the key applicants that are active in this field of research, featuring company-specific details (such as year of establishment, and location of headquarters), and inputs on their respective IP publication trends. 
    
Sheet 10 features an analysis of the most popular CPC symbols and CPC families (in terms of frequency of appearance in the dataset) related to lipid nanoparticles in drug delivery. 

Sheet 11 is an appendix, which includes pivot tables that drive the charts and interactive elements for the complete IP landscape depicted in sheet 2 of the deliverable.

Sheet 12 is an appendix, featuring details related to the categorization done in the report, and important abbreviations used in reference to the data categories mentioned in the document. 

PowerPoint Deliverable
Chapter 1 briefly describes of the rising applications of lipid nanoparticles in drug delivery and its key advantages. Further, it provides an overview of the intellectual property landscape related to lipid nanoparticles in drug delivery. 

Chapters 2 and 3 feature brief (pictorial) summaries of the approach used during data collection for this project, and the key objectives of the study.

Chapter 4 is an executive summary of the important insights and key takeaways, generated from analyzing the IP landscape of lipid nanoparticles in drug delivery.

Chapter 5 offers a general overview of the lipid nanoparticles and various methods of preparation of lipid nanoparticles. Further, it provides a summary of the important milestones in this field of lipid nanoparticles and their applications in drug delivery. Additionally, the chapter highlights the advantages, as well as application areas of lipid nanoparticles as drug delivery systems and the future perspectives associated with this domain.

Chapter 6 includes a review of the various patents and affiliated IP documents that have been published related to lipid nanoparticles in drug delivery, since the year 1977. It also features an in-depth analysis of published IP documents, representing unique patent families across various global jurisdictions, and includes insightful inferences related to both historical and recent R&D trends within this niche, yet rapidly evolving applications the healthcare segment.

Chapter 7 features an insightful examination of IP literature, highlighting key words and phrases that are used to describe lipid nanoparticles in drug delivery, including information on historical usage in IP filings, key affiliated terms (which can be used to identify other relevant IP search terms and establish relationships between prior art search expressions), and other related trends.

Chapter 8 offers insights from a competitive benchmarking and valuation analysis of the key members of unique patent families that have been captured in the report. It takes into consideration important parameters, such as type of IP document, year of application, time to expiry, number of citations and jurisdiction (factoring in value associated with the gross domestic product (GDP) of a particular region).

Chapter 9 provides a detailed summary of the patent applications (representative of unique patent families) that were filed across different jurisdictions and their relative value in the IP ecosystem. The analysis segregates the captured intellectual capital in terms of type of innovation and the specific innovation (different product classes, enabling technologies or methods of use), thereby, offering the means to identify active arenas of research and assess innovation-specific IP filing trends. Further, it features an analysis that helps identify relevant areas of innovation by analyzing published IP documents (representative of unique patent families), defining the uniqueness of patent pending innovations, in order to assess the scope of patentability in this domain, and pinpoint jurisdictions where new and / or modified claims may be filed without infringing on existing IP.

Chapter 10 is an elaborate summary of the granted patents (representative of unique patent families) across different global jurisdictions and their relative value in the IP ecosystem. The analysis also features a meaningful classification system, segregating granted IP into relevant categories (namely type of innovation and innovation) in order to help develop a detailed perspective on the diversity of intellectual capital (having marketing exclusivity) related to lipid nanoparticles in drug delivery and assessing the likelihood for innovators to enter into promising product markets, once active patents expire. Further, it features an analysis that helps identify relevant areas of innovation by analyzing published IP documents (representative of unique patent families), defining the uniqueness of patented innovations, in order to assess the scope of patentability in this domain, and pinpoint jurisdictions where new and / or modified claims may be filed without infringing on existing IP.

Chapter 11 features profiles of some of the most popular applicant companies, which were shortlisted based on their respective patent filing activities. Each profiles includes a brief overview of the company, information on annual revenues (wherever available), details on its initiatives undertaken in the area of lipid nanoparticles and its use in drug delivery, names of key management team members and recent developments. 

Chapter 12 includes an insightful analysis of the various CPC symbols mentioned in published IP literature (representative of unique patent families) and their affiliated families, offering the means to identify historical and existing pockets of innovation (based on the functional area / industry described by the elaborate and systematic IP classification approach, mentioned earlier); the analysis also features a discussion on prevalent white spaces (based on type of innovation and innovation) in this field of research.

Chapter 13 concludes the report by summarizing publicly available insights on the anticipated developments in this domain (taking into consideration the perspectives of eminent representatives of stakeholder companies in this industry), and trends that are likely to shape the future of lipid nanoparticles in drug delivery.

Chapter 14 is a set of appendices, entailing an overview of the excel research report, a list of IP documents featuring the identified white spaces, table of contents, list of figures, list of tables, glossary, and list of all the applicant companies and organizations.

Table Of Contents

Excel Deliverable

1. Research Notes

2. Summary Dashboard
A. Overall Intellectual Property Landscape
B. Intellectual Property Landscape (Grouped by Simple Families)
C. Key Prior Art Search Expressions
D. Key Trends related to Patent Applications (featuring Patentability and Freedom to-Operate)
E. Key Trends related to Granted Patents (featuring Patentability and Freedom-to-Operate)
F. Claims Analysis
G. Key CPC Symbols
H. Key Applicants

3. Overall Intellectual Property Landscape Dataset

4. Prior Art Search Expressions (Keyword Analysis)

5. Patent Applications Dataset

6. Granted Patents Dataset

7. Claims Analysis

8. Key Applicants Analysis

9. CPC Analysis

10. Appendix I: Pivot Tables

11. Appendix II: Country / Geography Codes

12. Appendix III: Innovation Categories

PowerPoint Deliverable

1. Context

2. Project Approach

3. Project Objectives

4. Executive Summary

5. Lipid Nanoparticles in Drug Delivery
5.1. Overview
5.2. Introduction to Lipid Nanoparticles
5.3. Advantages and Applications of Lipid Nanoparticles in Pharmaceutical Industry
5.4. Future Perspectives

6. Overall Intellectual Property Landscape
6.1. Overview
6.2. Analysis of Simple Patent Families
6.3. Key Innovation Categories
6.4. Insights from Patent Applications
6.5. Insights from Granted Patents

7. Key Prior Art Search Expressions
7.1. Overview
7.2. Analysis of Prior Art Search Expressions

8. Intellectual Property Valuation Analysis
8.1. Valuation Overview
8.2. Analysis of Individual Value Ranks
8.2.1. Rank 1 IP Documents
8.2.2. Rank 2 IP Documents
8.2.3. Rank 3 IP Documents
8.2.4. Rank 4 IP Documents
8.2.5. Rank 5 IP Documents
8.3. Concluding Remarks
8.4. List of Rank 1 IP Documents

9. Analysis of Patent Applications
9.1. Overview
9.2. Relative Valuation of Patent Applications
9.3. Patentability and Freedom-to-Operate

10. Analysis of Granted Patents
10.1. Overview
10.2. Relative Valuation of Grated Patents
10.3. Patentability and Freedom-to-Operate
10.4. Analysis of Patent Claims (Granted Active Patents)

11. Key Applicants
11.1. Overview
11.2. Analysis of Key Applicants
11.2.1. Company A
11.2.2. Company B
11.2.3. Company C
11.2.4. Company D
11.2.5. Company E
11.2.6. Company F
11.2.7. Company G
11.2.8. Company H
11.2.9. Company I
11.2.10. Company J

12. Pockets of Innovation and White Spaces
12.1. Overview
12.2. Pockets of Innovation
12.3. White Spaces
12.4. Concluding Remarks

13. Future Outlook
13.1. Lipid Nanoparticles in Drug Delivery: IP Filing Growth Trends
13.2. Relevance of IP for Business Development and Growth
13.3. Contemporary Sentiments and Predictions
13.4 Anticipated Future Developments and Trends

14. Appendices

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. Aarhus University
  2. 3M Innovative Properties
  3. Abbott
  4. Abcombi Biosciences
  5. ABIONYX Pharma
  6. AC BioScience
  7. AC Immune
  8. Academia Sinica
  9. Access Pharma
  10. ACM Biolabs
  11. ACT Therapeutics
  12. Acuitas Therapeutics
  13. Adjuvantix
  14. Aduro BioTech
  15. Advanced BioScience Laboratories (ABL)
  16. Advanced Cardiovascular Systems
  17. Advanced Inhalation Research
  18. Advaxis
  19. Aegis Therapeutics
  20. AfGin Pharma
  21. Agency for Science, Technology and Research (A*STAR)
  22. AGENE Research Institute
  23. Agenus
  24. Agilent Technologies
  25. AgoneX Biopharmaceuticals
  26. AgResearch
  27. AgroSource
  28. Akagera Medicines
  29. Albany Medical College
  30. Albert Einstein College of Medicine
  31. Albumedix
  32. Alcon
  33. Alcyone Therapeutics
  34. Aleph Therapeutics
  35. Alexion Pharmaceuticals
  36. Alloplex Biotherapeutics
  37. Almac Discovery
  38. Alnylam Pharmaceuticals
  39. Alpharma
  40. ALSATECH
  41. Altea Therapeutics
  42. Altus Pharmaceuticals
  43. ALZA Corporation
  44. Alzeca Biosciences
  45. Amorepacific Corporation
  46. Amur Pharmaceuticals
  47. Ancora Pharmaceuticals
  48. Angarus Therapeutics
  49. Angioslide
  50. Annexin Pharmaceuticals
  51. Antex Biologics
  52. Antipodean Pharmaceuticals
  53. APA Technologies (APAT)
  54. Aphton
  55. Apogee Technology
  56. Apollo Life Sciences
  57. Applaud Medical
  58. Applied Biology
  59. Aptorum Therapeutics
  60. Aradigm
  61. Arbutus Biopharma
  62. Arcturus Therapeutics
  63. Ares Trading
  64. Aridis Pharmaceuticals
  65. Arsanis Biosciences
  66. Artizan Biosciences
  67. Arytha Biosciences
  68. Asahi India Glass
  69. Ascendia Pharmaceuticals
  70. Astellas Pharma
  71. AstraZeneca
  72. Asymmetric Therapeutics
  73. Athena Neurosciences
  74. Atossa Therapeutics
  75. Atrium Medical
  76. Atrix Laboratories
  77. Auburn University
  78. Aurelium BioPharma
  79. Austria Wirtschaftsserv
  80. Avalon GloboCare
  81. Avanti Polar Lipids
  82. AVI BioPharma
  83. Avidea Technologies
  84. Axceso Biopharma
  85. Axolabs
  86. Axon Neuroscience
  87. AyuVis Research
  88. Bangor University
  89. Bar-Ilan University
  90. Bausch + Lomb
  91. Bausch Health
  92. Baxter
  93. Bayer
  94. Bayer Animal Health
  95. Baylor College Medicine
  96. Baylor Research Institute
  97. BC Cancer Agency
  98. BD
  99. Beckman Coulter
  100. Beijing Luzhu Biotechnology
  101. Beijing WeHand Bio Pharmaceutical
  102. Beijing Xinde Runxing Technology
  103. Benebiosis
  104. Ben-Gurion University
  105. BetterLife Pharma
  106. Bharat Biotech
  107. Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh
  108. Biocarb
  109. BioCardia
  110. Biocompatibles
  111. BIOINFRA Life Science
  112. BioLeaders
  113. Biolitec Pharma
  114. Biomas
  115. Biome Environmental Solutions
  116. Biomedical Research Models
  117. bioMerieux
  118. BiondVax Pharmaceuticals
  119. Bioneer
  120. Bionor Immuno
  121. BioNTech
  122. BioPath Holdings
  123. Biosource Pharm
  124. Biotechnology Forschung
  125. Biotechnology Research Center
  126. BioXcel
  127. Boehringer Ingelheim
  128. BONAC corporation
  129. Boston Scientific
  130. Boston University
  131. Bracco
  132. BrainsGate
  133. Brigham and Women's Hospital
  134. Bristol Myers Squibb
  135. Bullet Biotechnology
  136. C3J Therapeutics
  137. California Institute of Technology
  138. CAMRIS
  139. Canadian Blood Services
  140. Cancer Research Technology
  141. CanSino Biologics
  142. Capten Therapeutics
  143. Carantech BioSciences
  144. CardioVax
  145. Carnegie Mellon University
  146. Catalent
  147. Catholic University of Louvain
  148. Cedars-Sinai Medical Center
  149. Celator Pharmaceuticals
  150. Cell X Technologies
  151. Cellectar Biosciences
  152. Cellectis
  153. Celsion
  154. Celsus Therapeutics
  155. Center for Molecular Immunology
  156. Center for Molecular Medicine and Immunology
  157. Centocor
  158. CeramOptec
  159. CFD Research
  160. CHA University
  161. CHA Vaccine Institute
  162. Chang Gung University
  163. Chemo-Sero-Therapeutic Research Institute
  164. Chengdu Ribocure Pharmatech
  165. Chiba University
  166. Children's Medical Center Corporation
  167. Children's National Hospital
  168. Chimerix
  169. China Pharmaceutical University
  170. Chiron Corporation
  171. Chongqing Jiachen Bioengineering
  172. Chonnam National University
  173. Chugai Pharmaceutical
  174. CisThera
  175. CiVi Biopharma
  176. Clarion Pharmaceuticals
  177. Claudius Regaud Institute
  178. Clear Direction
  179. Cleveland Clinic
  180. Cleveland State University
  181. Clonit
  182. Cocrystal Pharma
  183. Codiak BioSciences
  184. Coley Pharm
  185. Collagen Corporation
  186. Columbia University
  187. Combined Therapeutics
  188. Complutense University of Madrid
  189. Compugen
  190. Concept Medical Research
  191. Connecticut Children's Medical Center
  192. ConserV Bioscience
  193. Convergent RnR
  194. Corixa Corporation
  195. Cornell Research Foundation
  196. Cornell University
  197. Council of Scientific & Industrial Research
  198. Counterpoint Biomedica
  199. Creighton University
  200. Critical Pharmaceuticals
  201. CRM Therapeutics
  202. CryoLife
  203. CSL
  204. CSL Seqirus
  205. CTT Cancer Targeting Technologies
  206. Cuprous Pharmaceuticals
  207. Curadev Pharma
  208. CureVac
  209. CytImmune
  210. Cytos Biotechnology
  211. Czech Academy of Sciences
  212. D4 Labs Interactive Technologies
  213. Daiichi Sankyo
  214. Dako Denmark
  215. Dalhousie University
  216. Dalian Minzu University
  217. Dana–Farber Cancer Institute
  218. Dartmouth College
  219. Datt Life Sciences
  220. Dcv Biologics
  221. Delex Therapeutics
  222. Dendritic NanoTechnologies
  223. Denka
  224. Department for Environment, Food & Rural Affairs
  225. Department of Chemistry and Chemical Biology at Rutgers University
  226. DepoTech
  227. DermaTrends
  228. Development Center for Biotechnology (DCB)
  229. Dexcel Pharma
  230. Diadem Biotherapeutics
  231. Distributed Bio
  232. Domantis
  233. Doosan
  234. D-Pharm
  235. DPM Therapeutics
  236. Dresden University of Technology
  237. Dsm IP Assets
  238. Duke University
  239. Dynavax Technologies
  240. Dyve Biosciences
  241. EDH Biotech
  242. Edison Oncology
  243. Eisai
  244. Elan Drug Technologies
  245. Elanco
  246. Electrosols
  247. Elicio Therapeutics
  248. Elwha
  249. EMED Technologies
  250. Emergent Product Development Gaithersburg
  251. Emory University
  252. EMV Enhance
  253. ENB Therapeutics
  254. Enbio
  255. Endorex
  256. Engimata
  257. EnhancedBio
  258. EntreMed
  259. Entropy Solutions
  260. Envisagenics
  261. Enzymotec
  262. EP Technologies
  263. Epimmune
  264. EPITARGET
  265. EpiVax
  266. Erasmus University Medical Center
  267. Eriochem
  268. eTheRNA Immunotherapies
  269. Ethicon
  270. EuBiologics
  271. Eureka Therapeutics
  272. Euro-Celtique
  273. Evox Therapeutics
  274. Ewha University-Industry Collaboration Foundation
  275. Exicure
  276. Experimental Pharmacology & Oncology Berlin-Buch
  277. Exponential Biotherapies
  278. EyeGene
  279. Ezaki Glico
  280. Farnex
  281. Federal University of Minas Gerais
  282. First Necessity
  283. First Time US Generics
  284. Fish Biotech
  285. Flagship Pioneering
  286. FMC BioPolymer
  287. Fondazione Toscana Life Sciences
  288. Fonterra
  289. Forskarpatent
  290. Fudan University
  291. Fujifilm
  292. G Tech Bio
  293. Galenica
  294. GC Biopharma
  295. Gene Tools
  296. Genelux
  297. Genentech
  298. Generex Pharmassist
  299. Genesis Group
  300. Genevant Sciences
  301. Genexine
  302. Genmab
  303. GenQuest
  304. Genus Oncology
  305. Genzyme
  306. George Mason Research Foundation
  307. Georgetown University
  308. Georgia Tech Research Institute
  309. Geron
  310. Ghent University
  311. Gilead Sciences
  312. Glactone Pharma
  313. GlobalAcorn
  314. GP Medical
  315. GreenLight Biosciences
  316. Griffith University
  317. Grinberg Sarina
  318. Gritstone bio
  319. GSK
  320. Guangzhou Argorna Biopharmaceuticals
  321. Guangzhou University of Chinese Medicine
  322. Guy's and St Thomas' NHS Foundation Trust
  323. H&A PHARMACHEM
  324. Hadasit Medical Research Services & Development
  325. Hallym University
  326. Halo Science
  327. Hamamatsu University School of Medicine
  328. Hana Biosciences
  329. Hangzhou DAC Biotech
  330. Hangzhou Xingao Biotechnology
  331. Hangzhou Yuhong Pharmaceutical Science & Technology
  332. Hanyang University
  333. Harbor Medical
  334. Harvard College
  335. Hawaii Biotech
  336. Health Protection Agency
  337. Heidelberg Pharma
  338. Heidelberg University
  339. HemoShear
  340. Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF)
  341. HERMES Biosciences
  342. HiberCell
  343. HIPRA
  344. Hokkaido University
  345. HTD Biosystems
  346. Human BioMolecular Research Institute
  347. i.com medical
  348. IBC Pharmaceuticals
  349. Icahn School of Medicine at Mount Sinai
  350. ICH Productions
  351. Icure BNP
  352. ID Biomedical
  353. Igeneon Krebs-Immuntherapie
  354. ImaRx Therapeutics
  355. Immune Targeting Systems
  356. ImmunityBio
  357. Immuno Rx
  358. ImmunoCellular Therapeutics
  359. ImmunoFrontier
  360. Immunolight
  361. Immunomedics
  362. IMP Innovations
  363. Imperial Chemical Industries (ICI)
  364. Imperial College Innovations
  365. Imperial College London
  366. Imugene
  367. IMV Inc.
  368. Ind Academic Coop
  369. Indena
  370. Indian Institute of Technology Bombay
  371. Indiana University
  372. Industrial Cooperation Foundation, Chonbuk National University
  373. Industrial Technology Research Institute
  374. Inex Pharmaceuticals
  375. Infectious Disease Research Institute (IDRI)
  376. Inimmune
  377. Inis Biotech
  378. Inmunotek
  379. InnoMedica
  380. InnoPharma
  381. Innovation Ulster
  382. InPharma
  383. Insmed
  384. Institut Curie
  385. Institute for Advanced Study-Louis Bamberger and Mrs Felix Fuld Foundation
  386. Institute for Bioengineering of Catalonia
  387. Institute for Research in Biomedicine
  388. Institute for Viral Diseases and Immunoprophylaxis (IVI)
  389. Institute of Basic Medical Sciences (IBMS)
  390. Institute of Cellular Biology and Pathology
  391. Institute of Experimental and Technological Biology (iBET)
  392. Institute of Immunology
  393. Institute of Materia Medica
  394. Institute of Molecular and Cell Biology
  395. Institute of Molecular Biotechnology (IMBA)
  396. Institute of Organic Chemistry and Biochemistry
  397. Institute Voor Dierhouderij
  398. Integral Technologies
  399. Integrated Nanotherapeutics
  400. Intensity Therapeutics
  401. Intercell
  402. International AIDS Vaccine Initiative
  403. International Centre for Genetic Engineering and Biotechnology (ICGEB)
  404. International Health Research Center of Barcelona
  405. International ImMunoGeneTics information system (IMGT)
  406. Introgene
  407. Invectors
  408. Invent Biotechnologies
  409. Inventprise
  410. InvivoGen
  411. ioGenetics
  412. Isis Innovation
  413. Israel Institute for Biological Research
  414. Israel Oceanographic and Limnological Research
  415. Istanbul University
  416. Janssen
  417. Japan Science and Technology Agency (JST)
  418. Jenner Biotherapies
  419. Jenner Technologies
  420. Jeong Pil
  421. Jeonnam Bioindustry Foundation
  422. Jiangsu KeyGEN BioTECH
  423. Jiangsu Lianhuan Pharma
  424. Jivana Biotechnology
  425. Johannes Gutenberg University Mainz
  426. Johns Hopkins University
  427. Josai University
  428. JSR Corporation
  429. Juvaris BioTherapeutics
  430. Kagoshima University
  431. Kansas State University
  432. Kao Corporation
  433. KAPAC
  434. KBP Biosciences
  435. Keio University
  436. Kennedy Krieger Institute
  437. Keraplast Technologies
  438. Kereos
  439. Keto Patent Group
  440. King Abdullah University of Science and Technology
  441. King's College London
  442. Kintara Therapeutics
  443. Kintor Pharmaceuticals
  444. Kitasato Daiichi Sankyo Vaccine
  445. Klaria Pharma
  446. Klinikum Rechts der Isar University Hospital at Technical University of Munich
  447. Kode Biotech
  448. Kodiak Sciences
  449. Korea Advanced Institute of Science & Technology (KAIST)
  450. Korea Institute of Geoscience and Mineral Resources
  451. Korea Institute of Science and Technology
  452. Korea Research Institute of Bioscience and Biotechnology
  453. Korea University of Research and Business Foundation
  454. Kumamoto University
  455. KV Pharmaceutical
  456. Kyowa Kirin
  457. Kyungpook National University
  458. Kyushu University
  459. L2 Diagnostics
  460. La Jolla Institute for Immunology
  461. LabyRx
  462. Lanco Biosciences
  463. Large Scale Biology Corporation
  464. Lawrence Livermore National Security
  465. Leidos
  466. Leland Stanford Junior University
  467. Liem Canet Santos
  468. Life Science Research Israel
  469. Life Technologies
  470. Linear Technologies
  471. Lipella Pharmaceuticals
  472. LiPlasome Pharma
  473. LipoMedix
  474. Liposoma Technology
  475. Lipotek
  476. Lipoxen Technologies
  477. Locus Agricultural Solutions
  478. Loewi
  479. Lohmann Therapie Systeme (LTS)
  480. London Health Sciences Centre
  481. Longhorn Vaccines & Diagnostics
  482. Louisiana State University
  483. Louisiana State University and Agricultural & Mechanical College
  484. Lpath Therapeutics
  485. LTT Bio-Pharma
  486. Ludwig Cancer Research
  487. Ludwig Maximilian University of Munich
  488. Luna Innovations
  489. Lynntech
  490. M Bio Technology
  491. Macfarlane Burnet Institute for Medical Research and Public Health
  492. MacRegen
  493. Malvern Instruments
  494. Marina Biotech
  495. Mashhad University of Medical Sciences
  496. Massachusetts Institute of Technology
  497. Maxim Pharmaceuticals
  498. Mayo Clinic
  499. MBC Pharma
  500. McDonnell Douglas Corporation
  501. McGill University
  502. McMaster University
  503. MD Anderson Cancer Center
  504. MD Labs
  505. Mecox Curemed
  506. Medarex
  507. Medeva Pharma
  508. Medical & Biological Laboratories
  509. Medical College of Wisconsin
  510. Medical Defense Technologies
  511. Medical University of Vienna
  512. MediGene
  513. MedImmune
  514. Medluminal Systems
  515. Megabios Corp
  516. Merck
  517. Merck Sharp & Dohme (MSD)
  518. Merrimack Pharmaceuticals
  519. Merrion Research
  520. Methodist Hospital Research Institute
  521. MetrioPharm
  522. Microdrug Ag
  523. Mie University
  524. Millennium Pharmaceuticals
  525. Minnow Medical
  526. Miravant Pharmaceuticals
  527. Mireca Medicines
  528. Mitsubishi Tanabe Pharma
  529. Moderna
  530. ModPro
  531. MOGAM Biotechnology Research Institute
  532. MOGAM Institute for Biomedical Research
  533. Molecular Express
  534. Molecular Machines
  535. Molecular Rebar Design
  536. Mologen
  537. Moreinx
  538. Morria Biopharmaceuticals
  539. Mucokinetica
  540. Murray Goulburn Co-operative Company
  541. MVRIX
  542. MX Adjuvac
  543. Myelin Repair Foundation
  544. Mymetics
  545. N4 Pharma
  546. Nagasaki University
  547. Nammi Therapeutics
  548. Nanjing CoreTech Biomedical
  549. Nanomed Devices
  550. Nanomed Skincare
  551. Nanoprobes
  552. Nant Holdings
  553. Nanyang Technological University
  554. Nastech Pharmaceutical
  555. NasVax
  556. National Cheng Kung University
  557. National Council for Scientific and Technical Research (CONICET)
  558. National Federation of Agricultural Cooperative Associations
  559. National Fisheries Research and Development Institute
  560. National Health Research Institutes
  561. National Institute for Materials Science
  562. National Institute of Advanced Industrial Science and Technology
  563. National Institute of Agricultural Research and Technology
  564. National Institute of Agricultural Technology (INTA)
  565. National Institute of Engineering
  566. National Institute of Health and Medical Research
  567. National Institute of Infectious Diseases
  568. National Institute of Psychiatry Ramon de la Fuente Muniz
  569. National Institutes of Health
  570. National Jewish Center for Immunology and Respiratory Medicine
  571. National Jewish Medical and Research Center
  572. National Research Council Canada
  573. National Research Development Corporation
  574. National Taiwan Ocean University
  575. National Tsing Hua University
  576. National University Hospital
  577. National University of Singapore
  578. National Yang Ming Chiao Tung University
  579. National Yang-Ming University
  580. Nektar Therapeutics
  581. NeoCura Bio-Medical Technology
  582. Neon Therapeutics
  583. Neopharm
  584. Neuroimmuno Therapeutics Research
  585. New Mexico Tech University Research Park Corporation
  586. New York University
  587. NeXstar Pharmaceuticals
  588. Nihon Medi-Physics
  589. NIPPON Genetics
  590. Nippon Shinyaku
  591. Nitto Denko
  592. NKD Pharma
  593. North American Vaccine
  594. Northeastern University
  595. Northern Illinois University
  596. Northwestern University
  597. Nostopharma
  598. Nova Pharm
  599. Novartis
  600. Novavax
  601. Novo Nordisk
  602. Novosom
  603. Novus International
  604. NSVascular
  605. Nuclisome Ab
  606. Nutricia
  607. Nutrimed Biotech
  608. OBI Pharma
  609. Ohio State University
  610. Oncothyreon
  611. Optime Therapeutics
  612. Oregon Health & Science University
  613. Orna Therapeutics
  614. Osaka University
  615. Ovid Therapeutics
  616. Palacky University Olomouc
  617. Paris Descartes University
  618. Paris Diderot University
  619. Partners for Utvecklingsinvesteringar inom Life Sciences
  620. PDS Biotechnology
  621. Peking University
  622. Percans Oncology
  623. Persephone Biosciences
  624. Pharma Logic
  625. PharmaDerm Laboratories
  626. PharmaExceed
  627. PHARMAFILM
  628. Pharmexa
  629. Phylex Biosciences
  630. Pierre and Marie Curie University
  631. Politehnica University of Bucharest
  632. Potentia Pharmaceuticals
  633. Prolexys Pharmaceuticals
  634. ProNAi Therapeutics
  635. Protiva Biotherapeutics
  636. Providence Therapeutics
  637. PX'Therapeutics
  638. Qantu Therapeutics
  639. Qingdao Harwars Biomedicine Technology
  640. QPS Holdings
  641. Quadrant Holdings Cambridge
  642. Quadrel
  643. Qualitas Health
  644. Quantum Materials
  645. Queen's University Belfast
  646. Quratis
  647. Race Oncology
  648. Ractigen Therapeutics
  649. Raven Biotechnologies
  650. Realinn Life Science
  651. Regeneron Pharmaceuticals
  652. Regional Centre for Biotechnology (RCB)
  653. Regional University Hospital of Lille (CHRU)
  654. Regulus Therapeutics
  655. RenovoRx
  656. Repertoire Immune Medicines
  657. Replicate Bioscience
  658. Research Institute for Development (IRD)
  659. Research Institute for Microbial Diseases of Osaka University
  660. Research Triangle Pharm
  661. Rhythm Pharmaceuticals
  662. Riboxx
  663. RITA Medical Systems
  664. RJAN Holding
  665. Roche
  666. Roche Diagnostics
  667. Rockefeller University
  668. Roehm
  669. ROVI
  670. Royal Free Hospital School of Medicine
  671. Royal Veterinary College
  672. Royer Biomedical
  673. Rutgers University
  674. Sahmyook University
  675. Saint Louis University
  676. Saitama Medical University
  677. Salk Institute for Biological Studies
  678. Samyang Biopharm
  679. San Diego State University
  680. Sandia National Laboratories
  681. Sandoz
  682. Sanford Burnham
  683. Sanofi
  684. Santen Pharmaceutical
  685. SANUWAVE Health
  686. Sapientia Pharmaceuticals
  687. Sapporo Medical University
  688. Schering
  689. SciMed Life System
  690. ScinoPharm Taiwan
  691. Scottish Agricultural College
  692. Scripps Clinic Research
  693. Scripps Research Institute
  694. SEARETE
  695. Seattle Children's Hospital & Regional Medical Center
  696. Seattle Children's Research Institute
  697. Second Genome
  698. Sederma
  699. Seikagaku Kogyo
  700. Selecta Biosciences
  701. Seneca College of Applied Arts and Technology
  702. Seoul National University R&DB Research Foundation
  703. Sequus Pharmaceuticals
  704. Serum Institute of India
  705. Shanghai Ginposome Pharmatech Company
  706. Shanghai Jiao Tong University School of Medicine
  707. Shanghai Second Medical Investment Management
  708. Shanghai Whittlong Pharmaceutical Institute
  709. Shenyang Pharmaceutical University
  710. Shenzhen Institute of Advanced Technology
  711. Shinshu University
  712. Sichuan University
  713. Sidney Kimmel Cancer Center
  714. Sigmoid Pharma
  715. Silence Therapeutics
  716. Singapore Health Services
  717. Sio2 Medical Products
  718. SipNose
  719. Sirna Therapeutics
  720. SiSaf
  721. Skyepharma
  722. Sloan Kettering Cancer Center
  723. Smart Drug Systems
  724. Sofia University "St. Kliment Ohridski"
  725. Sogang University
  726. SOLVE Research and Consultancy
  727. Sonus Pharmaceuticals
  728. Sony
  729. Sorbonne University
  730. Southwest Research Institute
  731. Squared Biotechnologies
  732. SRI International
  733. St Vincent's Hospital Sydney
  734. St. Anna Children's Cancer Research
  735. State University of Campinas (Unicamp)
  736. Stemirna Therapeutics
  737. Strand Therapeutics
  738. Sumitomo Chemical
  739. Sumitomo Pharma
  740. Sungkyunkwan University Research & Business Foundation
  741. SuperGen
  742. Superior Council of Scientific Investigations
  743. Superlab Far East
  744. Supratek Pharma
  745. Suzhou Abogen Biosciences
  746. Suzhou M-Conj Biotech
  747. Swiss Tropical and Public Health Institute
  748. Symbicom
  749. Symphogen
  750. SynGlyco Pharmaceuticals
  751. Synlife
  752. SynPharm
  753. Synthena
  754. Synvolux Therapeutics
  755. Taipei Medical University
  756. Taiwan Liposome Company
  757. Taizhou Guokehuawu Biomedical Technology
  758. Takeda
  759. Tarsius Pharma
  760. Tarveda Therapeutics
  761. Technical University of Denmark
  762. Technical University of Liberec
  763. Technical University of Munich
  764. Technion Research & Development Foundation
  765. Tehran University of Medical Sciences
  766. Teikyo University
  767. Tel Aviv University Future Technology Development
  768. Tel Hashomer Medical Research, Infrastructure and Services
  769. Telormedix
  770. Terumo
  771. Tessa Therapeutics
  772. Texas A&M University System
  773. Texas Children's Hospital
  774. Texas Tech University
  775. The Burlington Hc Research Group
  776. The Chinese University of Hong Kong
  777. The General Hospital Corporation
  778. The Giannina Gaslini Children's Hospital
  779. The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF)
  780. The Istituto Superiore di Sanità
  781. The Research Institute at Nationwide Children's Hospital
  782. The School of Pharmacy, University of London (LSOP)
  783. Texas Heart Institute
  784. University of Alabama
  785. University of Chicago
  786. Theratechnologies
  787. ThermoLase
  788. Thomas Jefferson University
  789. TianJin Medical University
  790. TianXinFu (Beijing) Medical Appliance
  791. Tiba Biotech
  792. Tidal Therapeutics
  793. TLC Biopharmaceuticals
  794. Tokai University
  795. Tokyo Medical and Dental University
  796. Tonen Corporation
  797. Tottori University
  798. Toulouse III - Paul Sabatier University
  799. TPCera
  800. Trained Therapeutix Discovery
  801. Transave
  802. Transcend Cytotherapy
  803. Transdermal Biotechnology
  804. Transgene Biotek
  805. Translate Bio
  806. Translational oncology (TRON)
  807. Transmed
  808. Transmedica
  809. Tufts University
  810. Tulane University
  811. UCL Business
  812. Ultrasonic Technologies (UST)
  813. Umoja Biopharma
  814. Universal Preservation Technologies
  815. University Health Network
  816. University of Alberta
  817. University of Amsterdam
  818. University of Arizona
  819. University of Arkansas
  820. University of Artois
  821. University of Bonn
  822. University of British Columbia
  823. University of Bruxelles
  824. University of Cagliari
  825. University of California
  826. University of Central Florida
  827. University of Chile
  828. University of Cincinnati
  829. University of Colorado
  830. University of Connecticut
  831. University of Copenhagen
  832. University of Delaware
  833. University of Florida
  834. University of Geneva
  835. University of Georgia
  836. University of Glasgow
  837. University of Granada
  838. University of Groningen
  839. University of Guelph
  840. University of Heidelberg
  841. University of Houston
  842. University of Illinois
  843. University of Iowa Research Foundation
  844. University of Konstanz
  845. University of KwaZulu-Natal
  846. University of Lausanne
  847. University of Leeds
  848. University of Lille
  849. University of Liverpool
  850. University of London
  851. University of Louisville Research Foundation
  852. University of Malaya
  853. University of Manitoba
  854. University of Maryland
  855. University of Maryland Biotechnology Institute
  856. University of Massachusetts
  857. University of Medicine and Dentistry of New Jersey
  858. University of Miami
  859. University of Michigan
  860. University of Minnesota
  861. University of Missouri
  862. University of Montana
  863. University of Montreal
  864. University of Montreal Hospital Center
  865. University of Nantes
  866. University of Nebraska
  867. University of North Carolina
  868. University of North Texas
  869. University of Notre Dame
  870. University of Lowa Research Foundation
  871. University of Otago
  872. University of Oklahoma
  873. University of Orleans
  874. University of Oxford
  875. University of Pennsylvania
  876. University of Pittsburgh
  877. University of Queensland
  878. University of Rochester
  879. University of Salamanca
  880. University of Sao Paulo
  881. University of Saskatchewan
  882. University of Sevilla
  883. University of Sheffield
  884. University of South Florida
  885. University of Southampton
  886. University of Southern California
  887. University of Tennessee Research Foundation
  888. University of Texas
  889. University of the Basque Country
  890. University of the Republic of Uruguay
  891. University of Toledo
  892. University of Tsukuba
  893. University of Utah
  894. University of Virginia
  895. University of Virginia Patent Foundation
  896. University of Washington
  897. University of Western Brittany
  898. University of Zaragoza
  899. University of Zurich
  900. US Department of Agriculture
  901. US Department of Commerce
  902. US Department of Health & Human Services
  903. US Department of Veterans Affairs
  904. US Government
  905. US Health
  906. Utrecht University
  907. Vaccitech
  908. ValiRx
  909. Vanderbilt University
  910. Vaxess Technologies
  911. VaxInnate
  912. VaxThera
  913. VBL Therapeutics
  914. VCC Medical Deutschland
  915. Vectron Therapeutics
  916. Vensica Medical
  917. Verseau Therapeutics
  918. VersiTech
  919. Vestar
  920. Vical
  921. Virun
  922. Vitruviae
  923. VIVUS
  924. VLP Therapeutics
  925. Vrije University of Amsterdam
  926. Vrije University of Brussel
  927. Vyome Therapeutics
  928. Wake Forest University Health Sciences
  929. Walter and Eliza Hall Institute of Medical Research
  930. Wayne State University
  931. West Pharmaceutical Services
  932. Willmar Poultry
  933. Wisconsin Alumni Research Foundation
  934. Wistar Institute
  935. Wyeth
  936. XEME Biopharma
  937. Xeris Pharmaceuticals
  938. Xiamen Ginposome Pharmaceutical
  939. Xiamen Sinopeg Biotech
  940. Xian Libang Biomedical Technology
  941. XI'an Libang Pharmaceutical
  942. Yale University
  943. Yamaguchi University
  944. Yamanouchi Pharmaceutical
  945. Yeda Research and Development Company
  946. Yissum Research Development Company
  947. Ziphius Vaccines
  948. Zoetis
  949. Zomanex
  950. ZoneOne Pharma
  951. Zydus Lifesciences

Source 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399483/
Source 2: https://themedicinemaker.com/manufacture/the-rise-of-lipid-nanoparticles

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.